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Thesis Abstract 
Epidemiological studies suggest that arsenic exposure is associated with various 
detrimental pregnancy outcomes. However, the mechanism for arsenic effects on 
pregnancy is unknown. We hypothesize that one of the reproductive outcomes, 
miscarriage, resulting from arsenic exposure may be due to placentation defects of 
pregnant mice, induced by endothelial vascular defects. The purpose of this study is to 1. 
Determine how arsenic exposure in drinking water affects fecundity, placentation and 
vascular morphogenesis in vivo. 2. Determine how arsenic exposure affects the balance 
between proliferation and apoptosis of bovine endothelial cells (BAE). The data show 
that the miscarriage rate is dramatically increased in pregnant mice exposed to arsenic in 
drinking water at concentration of 20 ppm (260 jjM) (52.6%), 37.5 ppm (0.49 mM) 
(61.0%) and 75 ppm (0.98 mM) (69.7%) compared to control (28%). The miscarriage 
rate of 37.5 ppm arsenic exposure group increases from 43% at E7.5 to 60% at E12.5. 
The vascular abnormalities of placentas and embryos at El2.5 stage are examined with 
bandeiraea simplicifolia lectin I isolectin B4 (BSL-B4) staining. There is significant 
decrease in the vasculature of sodium arsenite (Asm) treated placentas (52.0%). In vitro, 
we find a dose-dependent inhibition of cell growth and viability, and increased apoptosis 
by arsenic treatment for 24 hours on both confluent and non-confluent BAE cells. These 
data additionally suggest that confluent cells are more susceptible than proliferating cells 
to arsenic toxicity. However, proliferating cells are more susceptible in a loss of 
proliferation than confluent cells at doses of 5 pM and 10 jxM arsenic. In conclusion, the 
data suggest that arsenic exposure through drinking water in mice does not substantially 
affect litter size or pup weight, but does cause spontaneous abortion of the entire litter 
between E7.5 and El2.5, which finally results in increased miscarriage rate of pregnant 
mice exposed to 37.5 ppm arsenic. The effects may be due in part to abnormal placenta 
neovascularization of pregnant mice after arsenic exposure. 
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INTRODUCTION 
Arsenic is an omnipresent metalloid element naturally occurring in the environment in 
the earth's crust. It can be released into ground water and soil by both natural processes 
and human extractive activity. It also exists in pesticide and wood preservatives, 
pigments and glass (Waugh, 1982). Arsenic has organic and inorganic forms. There are 
two oxidation-states of inorganic arsenic: Arsenite (As111) and arsenate (Asv). These two 
forms speciate in the environment depending upon the level of dissolved oxygen. 
However, arsenate can be converted to arsenite in vivo (Abernathy et al., 1999) and it can 
be methylated by microbes to MMA (monomethylarsonic acid) and DMA 
(dimethylarsinic acid) (Vahter et al., 2001). This process is traditionally regarded as 
detoxification pathway because of less acute toxicity of organic arsenic, but a recent 
study suggests this may not be the case (Tonner-Navarro, 1998). Sodium arsenite (As111) 
was used throughout this project. The main source of human exposure to this toxicant is 
contaminated drinking water and some foods, such as rice, grains and fish (ACSH, 2002). 
Higher levels of arsenic contamination in drinking water from several hundred ppb to 
over 1 ppm have been observed in Argentina, Bangladesh, Chile, India, Mexico, Thailand 
and Taiwan (ACSH, 2002). In this country, some states, including Montana, New 
Mexico, Arizona, Nevada, Utah, Southern California, Idaho and Nebraska, have 50 ppb-
100 ppb of arsenic in drinking water; higher than the currently approved 10 ppb MCL 
(maximum contaminant level) (ACSH, 2002). 
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Human epidemiological data suggest an association between arsenic exposure in 
drinking water and adverse reproductive outcomes. Basically, they can be concluded into 
four main aspects. 
1. Spontaneous abortion. In 1989, it was reported that a 1.2-fold increased 
spontaneous abortion (95 % confidence interval: 1.0-1.6) was found in a community of 
286 women living with low levels of arsenic in drinking water (0.8-1.3 ppb) and a 1.7-
fold increased spontaneous abortion (95 % confidence interval: 0.7-4.2) was found in a 
community with high levels of arsenic (1.4-1.9 ppb) (Aschengrau et al., 1989). A study 
from Chile showed that higher incidence of late fetal mortality (rate ration (RR) = 1.7; 
95% confidence interval (CI), 1.5-1.9), neonatal mortality (RR = 1.52; CI, 1.4-1.7) and 
postneonatal mortality (RR = 1.26; CI, 1.2- 1.3) was associated with higher concentration 
of arsenic in drinking water (up to 860 ppb) compared to a control community (< 5ppb) 
(Hopenhanyn-Rich et al., 2000). 
2. Stillbirth. Borzsonyi et al. (1992) reported the potential risk of stillbirth 
resulted from arsenic in drinking water in southern Hungary. Another study group in 
Bangladesh found the rate of stillbirth (p< 0.046), spontaneous abortion (p< 0.008) and 
preterm birth rate (p< 0.018) significantly increased in the arsenic exposed group in 
drinking water (>0.1 ppm) comparing with lower level arsenic exposure group (<0.02 
ppm) (Ahmad et al., 2001). 
3- Preterm birth rate. A report from Taiwan suggested that there was a higher 
preterm birth rate (3.74 %) in a group with arsenic exposure in drinking water (from 0.9 
ppb up to 3.59 ppm) vs 3.43 % in a control group (<0.9 ppb) (with an odds ratio of 1.10). 
They also found that the babies' birth weight in an exposed group was on average 30 g 
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(95 % CI= 13.55- 44.55; P=0.002) lighter than those in a control group (Yang et al., 
2003). 
4 Birth weight. An epidemiologic study in 2003 from Chile suggested an average 
reduction of average birth weight (-57 g; 95% confidence interval = -123 to 9) was 
associated with higher level of arsenic in drinking water (42 ppb) compared to control 
community (<1 ppb) (Hopenhayn et al., 2003). 
These epidemiologic studies were limited by methodological concerns. Human data are 
too complicated for interpretation because there are multiple chemicals (copper, barium, 
fluoride etc) in drinking water and lifestyle factors could not be excluded. It is also 
difficult to determine chronic exposure levels in individuals to correlate the dose-
response effects for arsenic exposure. 
There are many experimental animal studies demonstrating arsenic as developmental 
toxicant, though the dosages of most of them are intravenous (i.v) or intraperitoneal (i.p) 
injection (Holson et al., 2000; Hood, 1978; Hood, 1972). These administration routes 
have made it difficult to assess the risk potential of arsenic on human health. Very few 
studies have examined the direct toxicity of arsenic exposure in drinking water on 
fecundity of pregnant mice, and none of them designed a dose-response study to 
determine the lowest concentration of As111 to cause toxicity in developing mice. 
Although both these human and experimental studies suggested an association between 
arsenic exposures in drinking water with detrimental pregnancy outcomes, it is not clear 
why this happens. Both the nutrition and toxicant are transferred to the developing 
embryo through the abundant placental vasculature. Inorganic arsenic of both oxidation 
states can easily cross the placenta as a low weight molecule (Desesso et al., 1998; 
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Dencker 1983; Lindgren 1984). Eastman first discovered that arsenic is accumulated in 
human placenta (Eastman, 1931; Desesso et al., 1998). Concha et al. (1998) found that 
arsenic in exposed maternal placenta was 34 |xg/kg, which was almost 5-fold higher than 
control women (7 |xg/kg) and most of the arsenic was in DMA (dimethylarsinic acid) 
form in the blood plasma of both mother and newborns. In terms of the mechanisms for 
fetal and embryonic arsenic toxicity, Hopenhayn et al. (2003) suggested that arsenic 
might have vascular effects and cause placental abnormalities or decreased blood flow, 
which then retard fetal growth. Further research is needed to provide a better 
understanding of the mechanisms for arsenic-induced developmental anomalies. 
Based on the current information, we hypothesize that arsenite toxicity impairs vascular 
development, causing abnormal placental neovascularization of pregnant mice that 
subsequently causes miscarriage. One purpose of this study is to determine how arsenic 
exposure affects fecundity, placentation and vascular morphogenesis in pregnant mice. 
Endothelial cells are the innermost lining of blood vessels that form the vascular 
network. They are the major places where nutrients and toxicants enter the blood vessel. 
They are also the frontier targets of toxicants on vascular networks, and the function of 
endothelial cells is the foundation of a functional and homeostatic vasculature. The 
balance between endothelial cell proliferation and apoptosis, resulting in the viability of 
endothelial cells, directly controls vascular differentiation and angiogenesis. We 
hypothesize that arsenite toxicity impairs vascular development causing an inadequate 
perfusion of tissues that subsequently causes miscarriage. To better understand the 
toxicity of arsenic on the vasculature, it is very important to study the effect of arsenic on 
endothelial cells. In embryonic life, endothelial cells actively proliferate and differentiate. 
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The apoptosis of endothelial cells can severely destroy vasculogenesis in embryo 
development and placenta and cord development, leading to serious hemorrhage, finally 
causing embryo death (Dimmeler et al., 2000). In contrast, in adult life endothelial cells 
are typically quiescent and turn over slowly, similar to the situation for confluent cells in 
culture. The apoptosis of endothelial cells in adult neovasculature can regulate the adult 
angiogenesis to avoid excess angiogenesis (Dimmeler et al., 2000). The differences 
among cultured confluent and non-confluent bovine aortic endothelial (BAE) cells may 
reflect how cells behave in vivo. A study from Brooks et al. (1994) using a monoclonal 
antibody antagonist of integrin avP3 selectively induced apoptosis in the proliferating 
vascular cells but not in quiescent endothelial cells, which suggested a difference in 
apoptosis susceptibility between quiescent and proliferating endothelial cells (Ranta et 
al., 1998). There is a need for a better understanding of the different sensitivity between 
confluent (quiescent) and non-confluent (replicating) endothelial cells in response to 
arsenic. The second specific aim of this study was to determine the different physiology 
of confluent and non-confluent cells altered by arsenic toxicity. To our knowledge, it's 
the first study on difference of proliferating and quiescent endothelial cells in response to 
arsenic. 
The vascular system develops through two different processes: vasculogenesis and 
angiogenesis. Vasculogenesis is the formation of new blood vessels de novo from 
precursor cells, which mainly occurs during embryo development and placenta creation 
(Poole et al., 1989). Angiogenesis is the sprouting of new capillaries from pre-existing 
blood vessel networks (Coffin et al., 1988). In the adult body, one characteristic of the 
vascular network is stability, and angiogenesis is normally absent (Charnock-Jones et al., 
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2004). However, angiogenesis could be activated and occur in certain circumstances, 
such as placentation (Gordon et al., 1995). The placenta is very crucial to pregnancy, 
providing adequate nourishment and oxygen to the fetus and exchanging wastes from the 
fetus. In humans, placental vasculature develops from gestational day 21 to delivery 
(Zygmunt et al., 2003) involving both vasculogenesis and angiogenesis processes. The 
angiogenesis in human placental vasculature is a complex and 3-dimentional process that 
involves sprouting, proliferation and migration of endothelial cells (Charnock-Jones et 
al., 2004). In this study, we investigated arsenic toxicity on endothelial cell physiology 
that underlies arsenic toxicity on placental angiogenesis. 
Knowledge of the cellular and molecular mechanism of arsenic toxicity on 
neovascularization in pregnancy is very important for better understanding human 
reproductive outcomes during arsenic exposure. Inhibition of endothelial cell apoptosis 
and increase of endothelial cell survival in placenta may improve the angiogenesis, thus 
helping with vascular development in embryo development. 
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CHAPTER 1. IN VIVO STUDY OF ARSENIC TOXICITY ON 
FECUNDITY AND VASCULAR DEVELOPMENT IN MOUSE 
INTRODUCTION 
Arsenic is an omnipresent metalloid element naturally occurring in the environment in 
the earth's crust. It can be released into ground water and soil by both natural processes 
and human extractive activity. It also exists in pesticide and wood preservatives, 
pigments and glass (Waugh, 1982). Arsenic has organic and inorganic forms. There are 
two oxidation-states of inorganic arsenic: Arsenite (As111) and arsenate (Asv). These two 
forms speciate in the environment depending upon the level of dissolved oxygen. 
However, arsenate can be converted to arsenite in vivo (Abernathy et al., 1999) and it can 
be methylated by microbes to MMA (monomethylarsonic acid) and DMA 
(dimethylarsinic acid) (Vahter et al., 2001). This process is traditionally regarded as 
detoxification pathway because of less acute toxicity of organic arsenic, but a recent 
study suggests this may not be the case (Tonner-Navarro, 1998). Sodium arsenite (As111) 
was used throughout this project. The main source of human exposure to this toxicant is 
contaminated drinking water and some foods, such as rice, grains and fish (ACSH, 2002). 
Higher levels of arsenic contamination in drinking water from several hundred ppb to 
over 1 ppm have been observed in Argentina, Bangladesh, Chile, India, Mexico, Thailand 
and Taiwan (ACSH, 2002). In this country, some states, including Montana, New 
Mexico, Arizona, Nevada, Utah, Southern California, Idaho and Nebraska, have 50 ppb-
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100 ppb of arsenic in drinking water; higher than the currently approved 10 ppb MCL 
(maximum contaminant level) (ACSH, 2002). 
Human epidemiological data suggest an association between arsenic exposure in 
drinking water and adverse reproductive outcomes. Basically, they can be concluded into 
four main aspects. 
1. Spontaneous abortion. In 1989, it was reported that a 1.2-fold increased 
spontaneous abortion (95 % confidence interval: 1.0-1.6) was found in a community of 
286 women living with low levels of arsenic in drinking water (0.8-1.3 ppb) and a 1.7-
fold increased spontaneous abortion (95 % confidence interval: 0.7-4.2) was found in a 
community with high levels of arsenic (1.4-1.9 ppb) (Aschengrau et al., 1989). A study 
from Chile showed that higher incidence of late fetal mortality (rate ration (RR) =1.7; 
95% confidence interval (CI), 1.5-1.9), neonatal mortality (RR = 1.52; CI, 1-4- 1.7) and 
postneonatal mortality (RR = 1.26, CI, 1.2-1.3) was associated with higher concentration 
of arsenic in drinking water (up to 860 ppb) compared to a control community (< 5ppb) 
(Hopenhanyn-Rich et al., 2000). 
2. Stillbirth. Borzsonyi et al. (1992) reported the potential risk of stillbirth 
resulted from arsenic in drinking water in southern Hungary. Another study group in 
Bangladesh found the rate of stillbirth (p< 0.046), spontaneous abortion (p< 0.008) and 
preterm birth rate (p< 0.018) significantly increased in the arsenic exposed group in 
drinking water (>0.1 ppm) comparing with lower level arsenic exposure group (<0.02 
ppm) (Ahmad et al., 2001). 
3. Preterm birth rate. A report from Taiwan suggested that there was a higher 
preterm birth rate (3.74 %) in a group with arsenic exposure in drinking water (from 0.9 
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ppb up to 3.59 ppm) vs 3.43 % in a control group (<0.9 ppb) (with an odds ratio of 1.10). 
They also found that the babies' birth weight in an exposed group was on average 30 g 
(95 % CI= 13.55- 44.55; P=0.002) lighter than those in a control group (Yang et al., 
2003). 
4. Birth weight. An epidemiologic study in 2003 from Chile suggested an average 
reduction of average birth weight (-57 g; 95% confidence interval = -123 to 9) was 
associated with higher level of arsenic in drinking water (42 ppb) compared to control 
community (<1 ppb) (Hopenhayn et al., 2003). 
These epidemiologic studies were limited by methodological concerns. Human data are 
too complicated for interpretation because there are multiple chemicals (copper, barium, 
fluoride etc) in drinking water and lifestyle factors could not be excluded. It is also 
difficult to determine chronic exposure levels in individuals to correlate the dose-
response effects for arsenic exposure. 
There are many experimental animal studies demonstrating arsenic as developmental 
toxicant, though the dosages of most of them are intravenous (i.v) or intraperitoneal (i.p) 
injection (Holson et al., 2000; Hood, 1978; Hood, 1972). These administration routes 
have made it difficult to assess the risk potential of arsenic on human health. Very few 
studies have examined the direct toxicity of arsenic exposure in drinking water on 
fecundity of pregnant mice, and none of them designed a dose-response study to 
determine the lowest concentration of As111 to cause toxicity in developing mice. 
Although both these human and experimental studies suggested an association between 
arsenic exposures in drinking water with detrimental pregnancy outcomes, it is not clear 
why this happens. Both the nutrition and toxicant are transferred to the developing 
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embryo through the abundant placental vasculature. Inorganic arsenic of both oxidation 
states can easily cross the placenta as a low weight molecule (Desesso et al., 1998; 
Dencker 1983; Lindgren 1984). Eastman first discovered that arsenic is accumulated in 
human placenta (Eastman, 1931; Desesso et al., 1998). Concha et al. (1998) found that 
arsenic in exposed maternal placenta was 34 ng/kg, which was almost 5-fold higher than 
control women (7 fig/kg) and most of the arsenic was in DMA (dimethylarsinic acid) 
form in the blood plasma of both mother and newborns. In terms of the mechanisms for 
fetal and embryonic arsenic toxicity, Hopenhayn et al. (2003) suggested that arsenic 
might have vascular effects and cause placental abnormalities or decreased blood flow, 
which then retard fetal growth. Further research is needed to provide a better 
understanding of the mechanisms for arsenic-induced developmental anomalies. 
Based on the current information, we hypothesize that arsenite toxicity impairs vascular 
development, causing abnormal placental neovascularization of pregnant mice that 
subsequently causes miscarriage. One purpose of this study is to determine how arsenic 
exposure affects fecundity, placentation and vascular morphogenesis in pregnant mice. 
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MATERIALS AND METHODS 
Chemicals Sodium arsenite (Formula: NaAs02, MW: 129.91) was purchased from J. T 
Baker (Phillipsburg, NJ), and diluted with deionized distilled water (ddFbO) to yield 0 
ppm (0 (xM), 10 ppm (130 |jM), 20 ppm (260 H.M), 37.5 ppm (0.49 mM), 75 ppm (0.98 
mM) and 150 ppm (1.9 mM) concentrations of drinking water for mice. It is changed 
twice weekly to maintain the desired oxidation states. 
Animals FVB/NJ strain mice (7-10 weeks age) were bred from our internal stocks. All 
mice were fed a diet of rodent chow (PMI, Brentwood, MO) and tap water ad lib. They 
were kept on a 12:12 h light: dark cycle at an environmental temperature of 22 ± 1.5°C, 
with a minimum relative humidity of 40 %. For mating, two virgin females were placed 
with one stud male and fed with deionized distilled water (ddt^O). The females were 
examined daily early morning for semen plug. Detection of a semen plug was designated 
day 0.5 (E0.5) of gestation. Pregnant females were placed in separate cages and exposed 
to As111 (Sodium Arsenite) through drinking water on a continuous basis throughout 
gestational and weaning stage. The control group was kept on ddl-hO. 
Data Collection The number of newborn pups was counted in both the arsenic-treated 
group and the control group. The pups were weighed weekly until weaning, when they 
were sacrificed. The frequency of delivery after plug was determined by number of 
plugged females produced babies divided by total number of plugged females. Prenatal 
viability was determined by number of plugged females with embryos alive divided by 
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total number of plugged females. Miscarriage rate was determined by number of plugged 
females not producing babies divided by total number of plugged females. Miscarriage 
rate at E7.5 and E12.5 was determined by number of plugged females not having 
embryos divided by total number of plugged females. 
Embryo examination At 7.5 and 12.5 days of gestation (E7.5 and E12.5), pregnant 
females were euthanized with carbon dioxide. The uterus was carefully transferred into 
sterile PBS and the number of live embryos or plaque resorptions was counted (data not 
shown). Live embryos were removed from their surrounding membranes and weighed. 
Due to the tiny weight of each embryo, all the live embryos of one litter weighed 
together. The mean embryo weight then generated by total weight divided by embryo 
numbers each litter. Embryos were stored in 4 % formalin/PBS at room temperature. 
BSL-B4 labeling of mouse tissue After mounting the 4 % formalin-PBS fixed 
placentas and embryos in frozen tissue matrix (VWR, Bristol, CT), 10 micron sections 
were cut on a Cryostat (England). (Mouse embryos were cut longitudinally). To stain the 
endothelial cells in placenta and embryo, fix tissues were soaked in CMPBS (PBS 
supplemented with 1 mM CaCh and 1 mM MgCh) 3 times, 5 minutes each. The tissues 
were then permeabilized with 100 % methanol for 20 minutes and rehydrated in ethanol 
series (95 %-70 %-50 %) for 2 minutes each. After rinsing in CMPBS two times, 
Bandeiraea simplicifolia lectin I isolectin B4 (BSL-B4) (Vector Laboratories, 
Burlingame, CA) (staining (1, 3)-Gal of endothelial cells) was applied (1 pg/mL in 
CMPBS) for 30 minutes at room temperature. After a rinse with CMPBS, Texas Red 
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(546) (Molecular Probes, Eugene, OR) was applied at 1:500 for 30 minutes. Following a 
final rinse in PBS, the slides were coverslipped with Fluorsave reagent (Calbiochem, San 
Diego, CA) and examined with a fluorescence microscope (Nikon Eclipse E600, Japan). 
The immunofluorescence staining was analyzed with a Laser scanning cytometer (LSC) 
(CompuCyte Corporation, Cambridge, MA). Each datum is an average of three repeated 
sections on each slide and 5 different embryo litters (one litter on one slide) in each 
group. 
Statistical analysis. Results are expressed as the mean ± standard deviation. 
Comparisons of means were analyzed by one-way analysis of variance (ANOVA) to 
determine intergroup differences. If the results of the ANOVA were significant (p< 0.05), 
Tukey's honestly significant difference (HSD) and Dunnett 2-sided test were applied to 
the data to compare the treated group with control groups. Frequency of delivery after 
plug and prenatal vibility were analyzed by one-way analysis of Chi-square test to 
determine at what percentage of confidence the difference between groups were caused 
by arsenic exposure in drinking water. 
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RESULTS 
Dose-response study 
To determine how arsenic exposure affected the fecundity of pregnant females, a 
preliminary dose-response study was done. Time-pregnant females were exposed to 0, 1, 
10, 20, 37.5, 75 or 150 ppm arsenic in drinking water on a continuous basis of gestational 
and weaning stages. The number of pups from each mother and average pup weight per 
litter at postnatal week 1, 2 and 3 was calculated (Table 1). There were strikingly 
increased miscarriage rates at 20 ppm (52.6 %), 37.5 ppm (61 %) and 75 ppm (69.7 %) vs 
control (28 %) (Table 2, Figure 1A). P value (<0.01) (Table 2) showed there is absolute 
dependence between the changing in miscarriage rate and the changing in arsenic 
exposure for these plugged mice. Although the pup number per litter in the arsenic 
treated group tended to be lower with increasing arsenic concentrations (from 1 ppm to 
37.5 ppm) compared to controls (Table 1, Figure IB), this finding was not statistically 
significant. We didn't see any significant difference in mean pup weight per litter in each 
arsenic treated group compared to control group either (Table 1, Figure 1C). To minimize 
the effects of maternal toxicity (The group treated with 150 ppm arsenic died 2-4 weeks 
after exposure.), the concentration of arsenic in drinking water used in subsequent 
experiments was focused on 20 and 37.5 ppm. 
Embryogenesis 
Effects of arsenic on developmental competence of embryos were examined at E7.5 
and E12.5 stages. The miscarriage rate for 20 ppm stayed the same at E7.5 and E12.5. 
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However, the miscarriage rate in 37.5 ppm arsenic group dramatically increased from 43 
% at E7.5 to 60 % at E12.5 (Table 3, 4, Figure 3A, Figure 4A). There was a clear dose-
response decrease of prenatal viability at El 2.5 (Table 4, Figure 3 A). However, the P-
value from chi-square test showed that miscarriage rates in 10 ppm, 20 ppm and 37.5 
ppm groups at El 2.5 stage are independent of arsenic exposure in drinking water (Table 
4). The same results were obtained at E7.5 stage (Table 3). Embryo number for each litter 
at El2.5 had a dose-related decrease (Table 4, Figure 3B), although the difference was 
not statistically significant. In contrast, we did not observe any decrease of embryo 
number of each litter mentioned above at E7.5 stage (Table 3, Figure 2B). We didn't 
observe any significant difference of mean pup weight in the various arsenic 
concentration groups comparing to control group at E7.5 or El2.5 (Table 3, Table 4, 
Figure 2C, Figure 3C). Figure 4 shows a summary of arsenic toxicity and its effects on 
pregnancy and embryonic development. The data show trend toward smaller litters at 
both the E12.5 and birth stages. The data also show trend toward lower birth weight with 
increasing arsenic toxicity at El 2.5. The most significant result is loss of the entire litter 
(P < 0.01), i.e. complete miscarriage, resulting from arsenic toxicity. 
Vasculature 
Placentas and embryos were examined for morphological variance and for vascular 
abnormalities. The insert micrograph (Figure 5E) shows three representative placentas 
from As"1 treated (top) and control (bottom) E12.5 females. The placentas of 37.5 ppm 
arsenic treated group were darker than those of control group may suggest a hemorrhage 
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and oxidation of hemoglobin. The enlargement of arsenic treated placentas may suggest a 
hypertrophy due to abnormal vasculogenesis (Figure 5E). 
Fixed placentas and embryos were stained with Bandeiraea simplicifolia lectin I 
isolectin B4 (BSL-B4) (staining (1, 3)-Gal of endothelial cells) and fluorescence was 
quantified with the laser scanning cytometer (LSC). There were numerous large cavities 
in the tissues and more loosening of cell connections in arsenic treated placenta (Figure 
5B) and embryo (Figure 5D) compared to control placenta (Figure 5A) and embryo 
(Figure 5C), which showed dramatic tissue damage. Quantification of fluorescence 
showed significantly loss of BSL-B4 positive staining (p<0.05) in placenta from 37.5 
ppm As111 treated group (51.99 %) at E12.5 versus the control group (100 %) (Figure 5E). 
The embryonic vasculature of this group decreased to about 65.69 % compared to control 
(100 %), though not statistically significant (Figure 5E). In contrast, the BSL-B4 labeling 
in 20 ppm arsenic treated placenta (122.09 %) didn't have any statistically significant 
difference compared to control placenta (100 %), nor did the BSL-B4 labeling in 20 ppm 
arsenic treated embryos (65.55 %) compared to control embryos (Figure 5E). 
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Table 1. Summary of arsenic effects on fecundity of pregnant mice 
Control 1ppm 10ppm 20ppm 37.5ppm 75ppm 
Numbers of plugged females with 
pups (n) 12 11 9 9 10 10 
Pups per litter (n) (mean ± SD) 9 ± 4 7.91 ±2.98 7.44 ±3.13 6.89 ± 2.47 5.55 ± 2.66 7.1 ±1.73 
Mean pup Weight (g) Week 1 4 15 ±0.62 4.60 ±0.68 4 78 ± 0.85 4.73 ± 1.31 4.29 ± 0.56 3.65 ± 0.5 
(Mean ± SD) Week 2 6.6 ± 1.50 7.25 ± 1.41 7.94 ± 1.55 7.35 ± 1.58 7.78 ± 1.32 5.43 ±0.7 
Week 3 9.88 ±2.73 10.99 ±2.07 11.48 ±2.14 10.88 ± 1.97 11.36 ± 1.56 8.17± 1.5 
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Table 2. Miscarriage rate for birth 
Control 1ppm 10ppm 20ppm 37.5ppm 75ppm 
Number of plugged females with pups (n) 13 11 9 9 11 10 
Number of plugged females without pups (n) 5 4 2 10 17 23 
Frequency of delivery after plug 72% 73% 81.8% 47.4% 39% 30.3% 
Miscarriage rate 28% 27% 18.2% 52.6% 61% 69.7% 
P-value (Chi-square test) P< 0.01 
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Figure 1. Dose-response relationship for arsenic toxicity on fecundity of pregnant mice. 
Plugged mice were exposed to various concentration of arsenic throughout all the 
gestational and weaning stages. Litters were counted and pups were weighted weekly. A. 
Calculated frequency of delivery after plug. B. Number of pups per litter. C. Mean pup 
weight per litter at week 1, 2 and 3 postnatal. Error bars represent the mean +/- SD for 
n>9 each group. 
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Table 3- Effects of arsenic toxicity on E7.5 embryo development 
Control 20ppm 37.5ppm 
Numbers of plugged females with embryos (n) 10 10 8 
Embryos per litter (n) (mean ± SEM) 7.9 ± 2.92 8.8 ± 1.99 8.38 ±3.81 
Mean embryo weight (g) (mean ± SEM) 0.0141 ±0.0054 0.0146 ± 0.0018 0.0139 ± 0.001 
Numbers of plugged females without embryos (n) 5 9 6 
Prenatal viability 67% 53% 57% 
Miscarriage rate (%) 33% 48% 43% 
P-value (Chi-square test) ns 
ns: not significant 
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Figure 2. Effect of arsenic toxicity on embryo development at E7.5. Plugged mice were 
exposed to various concentration of arsenic from E0.5 to E7.5. Live embryos were 
counted and weighed. A. Prenatal viability at E7.5. B. Numbers of embryo per litter at 
E7.5. C. Mean embryo weight per litter at E7.5. Error bars represent the mean +/- SD for 
n>8 each group. 
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Table 4. Effects of arsenic toxicity on E12.5 embryo development 
Control 10ppm 20ppm 37.5ppm 
Numbers of plugged females with embryos (n) 10 7 8 6 
Embryos per litter (n) (mean ± SEM) 8.9 ± 2.85 8.86 ± 2.97 8.38 ± 2.77 6.83 ± 2.5 
Mean embryo weight (g) (mean ± SEM) 0.0965 ± 0.040 0.0779 ±0.016 0.0828 ±0.020 0.076 ± 0. 
Numbers of plugged females without embryos (n) 2 2 7 9 
Prenatal viability 83% 77% 53% 40% 
Miscarriage rate (%) 18% 23% 50% 60% 
P-value (Chi-square test) ns 
ns: not significant 
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Figure 3- Effect of arsenic toxicity on embryo development at El2.5. Plugged mice were 
exposed to various concentrations of arsenic from E0.5 to E12.5. Live embryos were 
counted and weighed. A. Prenatal viability at El 2.5. B. Numbers of embryo per litter at 
E12.5- C. Mean embryo weight per litter at E12.5. Error bars represent the mean +/- SD 
for n> 6 each group. 
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Figure 5. Examination of vasculature of placenta and embryo at El 2.5. Pregnant mice 
were exposed to 0, 20 and 37.5 ppm arsenic from E0.5 till E12.5. Placentas and embryos 
were stained with BSL-B4 and quantified with LSC. (A) Control placenta. (B) 37.5 ppm 
arsenic exposed placenta. (C) Control embryo. (D) 37.5 ppm arsenic exposed embryo. 
(A-D) 20x magnification. (E) Amount of endothelial cells in placentas and embryos at 
E12.5. The amount of endothelial cells is expressed as percentage of control. Error bars 
represent the mean +/- SD for n=5 each group. Inset shows photographs of placentas 
before staining (lx magnification). 37.5 ppm arsenic exposed placentas in upper level. 
Control placentas in lower level. 
DISCUSSION 
Arsenic exposure through drinking water from E0.5 through weaning causes defects in 
placentation and lower fecundity in pregnant females. Drinking water exposure to sodium 
arsenite did not cause a statistically significant difference in the litter size at any time 
point. Our study suggests that primary effect of arsenic on pregnant mice was a dose-
dependent increase in conceptus mortality (miscarriage rate). Previous studies reported 
that embryonic malformations resulted from arsenic exposure by intraperitoneal (i.p.) or 
intravenous (i.v.) routes of pregnant mice (Hood, 1972; Morrissey, 1983). In this study, 
we didn't observe any obvious offspring malformations, which is consistent with the 
research results of Stump et al. (1999) that oral administration of arsenic in rats by 
gavage only resulted in increased prenatal mortality. We also didn't see any other adverse 
pregnancy outcomes, such as preterm delivery. All the pregnant females delivered at 19-
21 gestational days without any observable increase in stillbirth. We did not observe any 
obvious increase of the resorptions plaques atE12.5in37.5 ppm arsenic treated group 
compared to control group. To our knowledge, this is the first study associating arsenic 
exposure in drinking water with lower fecundity of pregnant females. However, the 
results of this study should be considered within the context of limitations in the study 
design. In our study, we didn't have exposure assessment and the consumption of arsenic 
water may vary between groups. 
In this study, we examined the E7.5 and El2.5 stages to monitor vascular development 
from when it is first evident to functionally accomplished. Comparison of E7.5 to 
neonatal stage miscarriage rates shows that the spontaneous abortion mostly happened in 
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postimplantation stage between E7.5 to El 2.5 stage. Examination of the placenta and 
embryonic vasculature showed arsenic toxicity impairs placental vascular development, 
which probably predisposes the embryo to miscarriage. In the 20 ppm arsenic treatment 
group, the miscarriage rate stayed almost the same from E7.5 (47 %), E12.5 (47 %) to 
birth (52 %). In contrast, the miscarriage rate for the 37.5 ppm arsenic treatment group 
increased from 43 % at E7.5 to 60 % at E12.5, which is within error, the same as the 61 
% rate at birth. These data suggest that the mechanisms for miscarriage caused by arsenic 
exposure at 20 ppm may be different from the mechanisms at 37.5 ppm. However, the 
reason for this difference is not clear. The high miscarriage rates at E7.5 (47 %) and 
E12.5 (43 %) may suggest that the pre-implantation stage is also an important stage for 
arsenic toxicity. The data for 20 ppm may suggest that pre-implantation is a critical time 
for arsenic toxicity related spontaneous abortion; versus 37.5 ppm treatments where the 
mechanism of arsenic toxicity may have two stages: pre-implantation and placental 
neovascularization during post-implantation. In 2002, Krininger et al. demonstrated that 
arsenic could impair the pre-implantation development of bovine embryos. They showed 
that apoptosis and group 2 caspase activity were increased after exposure to arsenic at E5 
(embryos >16 cells in number) and the cell number was reduced after exposure to 
arsenic at El.5 (two-cell stage). They also found that the percentage of embryos that 
developed to the blastocyst stage was reduced by arsenic exposure at both El .5 and E5 
(Krininger et al., 2002). The magnitude of increasing miscarriage rate at post-
implantation stage was less than that at pre-implantation stage, which is consistent with 
the report that developmental toxicity of inorganic arsenic was gestational age 
dependence (Tabacova et al., 1996). With increasing gestational age there was an 
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increasing resistance to arsenic-induced effects. In 1981, Harrison and Hood reported that 
exposure to arsenate by hamsters on E9 caused complete resorptions of all implantation 
sites while the same dose on El 1 and El2 only resulted in weight reduction (Harrison 
and Hood, 1981; Tabacova et al., 1996). However, current study indicates that another 
possibility is maternal oxidative stress induced by arsenic followed by abnormal placental 
neovascularization that is likely to make embryo more susceptible to arsenic toxicity. We 
found that the placentas and embryos in the arsenic treated group contained vascular 
morphological anomalies. These results are consistent with reports of cavernous damage 
to both endodermal epithelium and mesodermal mesothelium in arsenic treated mouse 
embryo and yolk sac placenta (Li et al., 1997). Likewise, we found decreased quantities 
of endothelial cells in the El 2.5 placenta of pregnant mice treated with 37.5 ppm (0.49 
mM) sodium arsenic in drinking water; which is consistent with the finding of Soucy NV 
et al. (2003) that concentration of arsenic greater than 1 |xM inhibits vessel growth in vivo 
in a chicken chorioallantoicmemebrane (CAM) assay. They also found that the threshold 
As111 concentration for this transition from stimulation to inhibition of vessel density is 
0.033 |jM. In summary, our study shows the development of embryo highly dependents 
on a functional placenta and functional disturbance of placenta could heavily impair 
embryo development. 
In this study, the different miscarriage rates for the control groups in the different 
experiments (Figure 4A) are likely to due to normal variance. Perhaps weighing the 
females before the experiments would have reduced the variance, though all of them were 
between 7 to 10 weeks age. 
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CHAPTER 2. A Comparison of Arsenic Toxicity on Viability, Proliferation and 
Apoptosis of Proliferating and Non-proliferating Bovine Aortic Endothelial Cells 
INTRODUCTION 
Endothelial cells are the innermost lining of blood vessels that form the vascular 
network. They are the major places where nutrients and toxicants enter the blood vessel. 
They are also the frontier targets of toxicants on vascular networks, and the function of 
endothelial cells is the foundation of a functional and homeostatic vasculature. The 
balance between endothelial cell proliferation and apoptosis, resulting in the viability of 
endothelial cells, directly controls vascular differentiation and angiogenesis. We 
hypothesize that arsenite toxicity impairs vascular development causing an inadequate 
perfusion of tissues that subsequently causes miscarriage. To better understand the 
toxicity of arsenic on the vasculature, it is very important to study the effect of arsenic on 
endothelial cells. In embryonic life, endothelial cells actively proliferate and differentiate. 
The apoptosis of endothelial cells can severely destroy vasculogenesis in embryo 
development and placenta and cord development, leading to serious hemorrhage, finally 
causing embryo death (Dimmeler et al., 2000). In contrast, in adult life endothelial cells 
are typically quiescent and turn over slowly, similar to the situation for confluent cells in 
culture. The apoptosis of endothelial cells in adult neovasculature can regulate the adult 
angiogenesis to avoid excess angiogenesis (Dimmeler et al., 2000). The differences 
among cultured confluent and non-confluent bovine aortic endothelial (BAE) cells may 
reflect how cells behave in vivo. A study from Brooks et al. (1994) using a monoclonal 
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antibody antagonist of integrin 0^3 selectively induced apoptosis in the proliferating 
vascular cells but not in quiescent endothelial cells, which suggested a difference in 
apoptosis susceptibility between quiescent and proliferating endothelial cells (Ranta et 
al., 1998). There is a need for a better understanding of the different sensitivity between 
confluent (quiescent) and non-confluent (replicating) endothelial cells in response to 
arsenic. The second specific aim of this study was to determine the different physiology 
of confluent and non-confluent cells altered by arsenic toxicity. To our knowledge, it's 
the first study on difference of proliferating and quiescent endothelial cells in response to 
arsenic. 
The vascular system develops through two different processes: vasculogenesis and 
angiogenesis. Vasculogenesis is the formation of new blood vessels de novo from 
precursor cells, which mainly occurs during embryo development and placenta creation 
(Poole et al., 1989). Angiogenesis is the sprouting of new capillaries from pre-existing 
blood vessel networks (Coffin et al., 1988). In the adult body, one characteristic of the 
vascular network is stability, and angiogenesis is normally absent (Charnock-Jones et al, 
2004). However, angiogenesis could be activated and occur in certain circumstances, 
such as placentation (Gordon et al., 1995). The placenta is very crucial to pregnancy, 
providing adequate nourishment and oxygen to the fetus and exchanging wastes from the 
fetus. In humans, placental vasculature develops from gestational day 21 to delivery 
(Zygmunt et al., 2003) involving both vasculogenesis and angiogenesis processes. The 
angiogenesis in human placental vasculature is a complex and 3-dimentional process that 
involves sprouting, proliferation and migration of endothelial cells (Charnock-Jones et 
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al., 2004). In this study, we investigated arsenic toxicity on endothelial cell physiology 
that underlies arsenic toxicity on placental angiogenesis. 
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MATERIAL AND METHODS 
Chemicals Sodium arsenite (Formula: NaAs02, MW: 129.91) was purchased from J. T 
Baker (Phillipsburg, NJ), and diluted with sterile PBS to yield arsenic concentrations of 
0, 1,5, 10, 20 and 50 |xM to treat BAE cells. 
Cell Culture Bovine aortic endothelial (BAE) cells were cultured in Dulbecco's 
modification of eagle's medium (DMEM) (Gibco, Grand Island, NY) supplemented with 
1 % penicillin-streptomycin-glutamine (PSG) (Hyclone Laboratores, Logan, Utah) and 
15 % fetal bovine serum (FBS) (Hyclone Laboratores, Logan, Utah). The cells were 
incubated at 37 °C in a humidified atmosphere of 5% CO2. The cells were harvested with 
0.05 % Trypsin-EDTA (Gibco, Grand Island, NY) and only passage between 2-6 were 
used. Cells reached confluence on 96 well plates and chamber slides two days after 
passage. One day post-confluent was used for all confluent cells. The culture medium for 
confluent cells was changed to fresh medium 18-24 hours before being treated with 
arsenic. Cells grown for one day (24 h) post-passage were considered non-confluent. Cell 
density was assayed with a Coulter Particle Counter (Beckman Coulter Corporation, 
Miami, FL). 
Cell viability assay Cell viability was determine with the modified MTT assay 
(Bunderson, et. al., 2002). Cells were seeded in 96 well plates at 1.5 x 105 cells/ml. 
Sodium arsenite solutions were applied for 24 hours. MTT (50 jig) (Sigma, St. Louis, 
MO) was added to each well and cells were incubated for four hours. Medium/MTT 
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solutions were removed and 100 fxL DMSO was added to dissolve the MTT formazan 
crystals. Absorbance was measured with Spectra Max 340 (Molecular Device, 
Sunnyvale, CA) at 550 nm. 
Cell proliferation assay BAE cells were seeded in 96 well plates at 1.5 x 105 cells/ml. 
After being treated with arsenic for 24 hours, a cell proliferation assay was performed 
with the use of BrdU (bromodeoxyuridine) Cell Proliferation Assay Kit (Oncogene, 
Cambridge, MA), according to the manufacturer's instructions. Absorbance was 
determined with Spectra Max 340 at dual wavelengths of 450-540 nm. 
TUNEL assay BAE cells were grown to confluence or non-confluence on 2% (w/v) 
gelatin (Sigma, St. Louis, MO) (diluted with PBS) coated Lab-Tek II Chamber slides 
(Nalge Nunc International, Naperville, IL) and incubated with arsenic concentrations of 
0, 1,5, 10, 20 or 50 ftM for 24 hours. A TUNEL (terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick end labeling) assay was performed with the use 
of ApoAlert DNA Fragmentation Assay Kit (Clontech, Palo Alto, CA) according to the 
manufacturer's instructions. Propidium iodide used in this assay was purchased from 
Sigma (St. Louis, MO). Fluorescence was quantified with a Laser Scanning Cytometer 
(LSC; CompuCyte Corporation, Cambridge, MA). 
Statistical analysis. Results are expressed as mean ± standard deviation. Comparisons of 
means were analyzed by one-way analysis of variance (ANOVA) to determine intergroup 
differences. If the results of the ANOVA were significant (p<0.05), Tukey's honest 
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significant difference (HSD) and Dunnett 2-sided test were applied to the data to compare 
the treated and control groups. 
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RESULTS 
Cell Viability assay 
Confluent and non-confluent BAE cells were grown in 96-well plates (1.5 x 105 
cells/ml) and a dose-response relationship to 24 hours of arsenic toxicity was determined 
with a MTT assay. There were dose-dependent decreases in viability after arsenic 
exposure in both confluent and non-confluent cells. In non-confluent cells, there was a 
significant decrease in viability from 5 |xM to 50 |xM compared to controls (Figure 6a), 
whereas confluent cells revealed a significant decrease in viability at arsenic 
concentration of 20 [aM and 50 jxM only (Figure 6b). However, at 50 |j.M arsenic 
exposure, the confluent cells had a significantly decreased cell viability compared to non­
confluent cells (Figure 6c), which may suggest confluent BAE cells are more susceptible 
to arsenic toxicity. 
Cell Proliferation assay 
Confluent and non-confluent BAE cells were grown in 96-well plates and a dose-
response study of cell proliferation was determined with the BrdU Proliferation Assay. 
Significant decreases in cell proliferation were found in proliferating (non-confluent) 
cells from 5 jxM to 50 jxM compared to control (Figure 7a); in contrast there was only a 
significant difference at highest concentration (50 |j,M) in confluent cells (Figure 7b). The 
non-confluent control BAE cells showed significantly more proliferation than confluent 
control cells. However, they only had significant difference at control and 1 |xM point and 
lost this difference at more than 1 ^M concentrations. This suggests that non-confluent 
BAE cells have more susceptibility to proliferation loss as a result of arsenic toxicity. 
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TUNEL assay for apoptosis 
Confluent and non-confluent BAE cells were seeded in gelatin coated chamber slides 
and a dose-response study of cell apoptosis to 24 hours arsenic toxicity was conducted 
with a TUNEL assay. There was a significant increase in BAE apoptosis in both 
confluent and non-confluent cells at 1, 10, 20 and 50 |jM sodium arsenite (Figure 8a, b). 
There was no significant difference between the two groups at any dose point (Figure 8c), 
though there was a trend of higher percentage of apoptosis cells in confluent BAE cells 
vs non-confluent cells. 
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Figure 6. Cell viability for confluent and non-confluent BAE cells treated with various 
concentration of sodium arsenite (As111) for 24 h. Viability was measured using an 
adaptation of MTT colorimetric assay as described under Methods. Viability is expressed 
as percentage of control (untreated cells); Error bars represent mean +/- SD for n=4. 
There is significant difference at all concentration point between confluent and non­
confluent cells (not marked). Significantly different from control p<0.05. The confluent 
control cells had higher viability (214 %) compared to non-confluent cells because they 
had 3 days longer to grow. 
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Figure 7. Cell proliferation for confluent and non-confluent BAE cells treated with 
various concentration of sodium arsenite (As111) for 24h. Cell proliferation was measured 
using BrdU cell proliferation assay (Oncogene, Cambridge, MA). There is significant 
difference between confluent and non-confluent cells at control and 1 |j,M arsenic 
treatment. The non-confluent control BAE cells showed significantly more proliferation 
(127 %) than confluent control cells (100 %). Proliferation is expressed as percentage of 
control (untreated cells); error bars represent mean +/- SD for n=4. * Significantly 
different from control, ** Significantly different between two group, p<0.05. 
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Figure 8. Cell apoptosis for confluent and non-confluent BAE cells treated with various 
concentration of sodium arsenite (As111) for 24h. Cell apoptosis was measured using 
ApoAlert DNA fragmentation assay (Clontech, Palo Alto, CA). Apoptosis is expressed as 
percentage of control (untreated cells); error bars represent mean +/- SD for n=4. 
Significantly different from control, p<0.05. 
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DISCUSSION 
Our data showing a dose-dependent decrease of cell proliferation in proliferating (non­
confluent) cells in response to arsenic treatment and a significant decrease starting from 5 
fiM are consistent with the decreased thymidine incorporation observed by others in 
exponentially growing porcine aortic endothelial cells (Barchowsky et al., 1996). This 
shows that the proliferation of non-confluent cells is not stimulated by arsenic at low 
concentration. In contrast, we observed a small trend of increasing cell proliferation from 
1 |xM to 5 fiM sodium arsenite in confluent cells (though not significant), which is 
consistent with the previous report that low concentration of arsenic has a mitogenic 
effect on postconfluent endothelial cells (Barchowsky, 1996). 
There was significant loss of cell viability of endothelial cells from 5 |xM in both 
confluent and non-confluent BAE cells in this study. This is consistent with previous 
findings that concentrations greater than 5 jxM are toxic to endothelial cells (Barchowsky, 
1996; Deneke, 1992). From the data, we found proliferating cells (non-confluent) had 
higher cell viability after exposure to 50 |nM arsenic for 24 than that of quiescent 
(confluent) cells, which may suggest a greater sensitivity of quiescent cells to arsenic 
toxicity. 
From the TUNEL assay, we did not observe any significant difference of increased 
apoptosis in response to arsenic treatment between confluent and non-confluent situation. 
There was only a trend of more apoptosis in quiescent BAE cells than proliferating cells, 
which may suggest the more sensitivity of quiescent cells vs proliferating cells to arsenic 
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toxicity which is consistent with the study from Queille et al. (2001) that growing cells 
had lower rates of apoptosis from UV damage than confluent cells. 
However, we observed significant increase of cell apoptosis in both confluent and non­
confluent situation compared to each control after 24 h treatment with 1 (xM arsenic and 
lost this significant difference at 5 fiM concentration followed by significant increase of 
apoptosis again. This is consistent with the study results from Barchowsky that there was 
no sign of cell death in primary porcine aortic endothelial cells exposure to 5 |xM 
arsenite, even following exposure for 96 hours (Barchowsky et al., 1999). They also 
reported a significant cell loss after 48 h with concentrations greater than 10 |xM, which 
agrees with the results showing here. In the other hand, low concentration of arsenic 
exposure (< 1 |uM) stimulates angiogenesis in vitro (Kao et al., 2003). Another study 
from Barchowsky et al (1996) demonstrated that oxidant generation (dichlorofluorescin 
(DCF)) peaked at 5 jxM sodium arsenite in porcine endothelial cells and decreased to 
basal line starting from 10 |xM arsenite. They also suggested that this increased 
intracellular oxidant formation promote nuclear translocation of trans-acting factors (NF-
KB) and therefore be mitogenic to endothelial cells growth. One implication from these 
literatures and the data of current study is that 1 |j,M - 5 jxM - 10 jxM may be a transit 
window of arsenic effects from stimulation angiogenesis to inhibition angiogenesis. The 
possible explanation for the phenomena we observed in TUNEL assay is that arsenic 
stimulates the apoptosis at 1 fiM, which is then compensated by the mitogenic effect of 
arsenic at 5 jxM and finally gets to inhibitory effect again at 10 fiM. 
At 50 jxM arsenic concentration, we observed a significantly less viability of confluent 
cells compared to non-confluent cells. In contrast, we didn't see any significant 
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difference of cell apoptosis or proliferation between confluent and non-confluent BAE 
cells. One of the reasons for that may be most of confluent cells are undergoing necrotic 
cell death instead of apoptosis. Previous research showed that bovine embryos can 
acquire increased resistance to certain cellular stress (cyanide toxicity) as they advance in 
development (Donnay et al., 2000). Like the actively proliferating cells in embryo, we 
can speculate that the surviving proliferating BAE cells may also gain a better resistance 
to exogenous toxicant (arsenic) than quiescent cells do. 
In conclusion, there was a dose-dependent inhibition of both cell proliferation and 
viability, and an increase in apoptosis by arsenic treatment for 24 hours on both confluent 
and non-confluent BAE cells. 
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CONCLUSIONS 
The major findings of this project were: Decreased fecundity in As111 exposed pregnant 
female mice due to vascular defects in the placenta (Chapter 1) and As111 mediated 
endothelial cell death (Chapter 2). Results from in vitro arsenic exposure experiments 
with BAE cells suggest that the defects in vascular development could result from a loss 
of endothelial cell viability; particularly in the placenta. The decline in the viability could 
result from lower proliferation, increased apoptosis, or a combination of both factors 
(Chapter 2). In conclusion, this study suggests As111 induced apoptosis and/or inhibition of 
proliferation in the developing placental endothelium may be the cause of the increased 
miscarriages in As111 exposed pregnant female mice. 
Future studies will address this hypothesis. Both the proliferation and apoptosis of 
endothelial cells will be assayed on placenta from As111 exposed mice. Currently, the 
mechanism of the regulation of angiogenesis in the placenta is not particularly well 
understood. Some endothelial growth factors, particularly vascular endothelial growth 
factor (VEGF), play very important roles in the process of vascular development. These 
growth factors may be the targets of an exogenous toxicant, resulting in vascular defects. 
It would also be interesting to study the differential expression of these proteins in 
placenta in response to arsenic toxicity in future research. 
Arsenic readily reacts with thiol-containing molecules such as GSH and cysteine, 
which are critical in biochemical reactions, leading to toxicity (Scott et al., 1993). 
However, the mechanism of arsenic toxicity in molecular level is still not very clear. 
Some studies suggested arsenic genotoxicity, such as chromosomal aberrations, DNA-
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protein crosslinks, and sister chromatid exchanges in hamster embryo cells after arsenic 
exposure (Rossman et al., 1980; Lee at al., 1985, Kochhar et al., 1996). Arsenic also 
alters DNA repair in human T-cell lymphoma cells by decreasing repair enzyme poly-
(ADP-ribose) polymerase at 10 fiM concentration, therefore causing decreased cell 
viability (Yager and Wiencke, 1997). Arsenic is also reported to cause some of the 
detrimental actions on cells by increasing superoxide anion generation (O2 ) and lipid 
peroxidation, which correlated with increased apoptosis of human gastric cancer cells 
(Chen et al., 2002). The reports referenced here and the results of this study clearly show 
that exposure to arsenic alters endothelial cell physiology. Does that alteration of 
endothelial cell physiology reach the threshold of pathological endothelial cell 
dysfunction? Collectively: The cardiovascular pathologies associated with arsenic 
toxicity in humans, in vitro studies exposing cultured endothelial cells to arsenic, and in 
vivo arsenic toxicity experiments such as this one all show that arsenic exposure causes 
endothelial dysfunction. 
Lee et al. demonstrated that arsenic increased the susceptibility of platelets to 
aggregate, leading to the increased risk of arterial thrombosis, which is a causal factor in 
the development of cardiovascular disease (Lee et al., 2002). This study and the results 
presented here strongly suggest that arsenic related endothelial cell dysfunction is directly 
linked to cardiovascular disease and developmental disorders. The necessary arsenic 
exposure levels and the nature of the endothelial cells dysfunction are clearly different in 
a tissue specific manner. For example, arsenic exposure to atherosclerotic mice results in 
endothelial dysfunction that accelerates atherogenesis (Bunderson et al., 2002). 
Conversely, this report shows that arsenic exposure to the developing embryo results in 
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endothelial dysfunction manifest as placental insufficiency that result in miscarriage. 
Future studies for this project will focus on endothelial cell dysfunction in the context of 
development. Particularly how arsenic mediated endothelial dysfunction affects 
angiogenesis and vasculogenesis, the two fundamental mechanisms for vascular 
development (Coffin and Poole, 1988). 
46 
ACKNOWLEDGMENTS 
This work was supported by the University of Montana Center for Environmental Health 
Sciences under NIH grants: NIEHS # 1R21 ESI 1749 and NCRR # 1P20RR17670. 
47 
BIBLIOGRAPHY 
Abernathy, C. O., Liu, Y. P., Longfellow, D., Aposhian, H. V., Bech, B., Fowler, B., 
Goyer, R., Menzer, R., Rossman, T., Phompson, C., and Waalkes, M. (1999). Arsenic: 
Health effects, mechanisms of actions, and research issues. Environ. Health Perspect. 
107, 593-597. 
Acosta, D., Kass, I. S., and Cottrell, J. E. (1987). Effect of free radicals. Exp. Neuro. 97, 
607-614. 
ACSH, (2002). Arsenic, drinking water, and health: a position paper of the American 
Council on Sciences and Health. Regulatory Toxicol. Pharmacol. 36, 162-174. American 
Council on Sciences and Health, New York. 
Ahmad, S.A., Sayed, M.H., Barua, S., Khan, M.H., Faruquee, M.H., Jalil, A., Hadi, S.A., 
and Talukder, H.K. (2001). Arsenic in drinking water and pregnancy outcomes. Environ. 
Health. Perspect. 109, 629-631. 
Aschengrau, A., Zierler, S., and Cohen, A. (1989). Quality of community drinking water 
and the occurrence of spontaneous abortion. Arch. Environ. Health 44, 283-90. 
Barbosa de Oliveira, L.G., Rocha Oliveira, C.J., Fries, D.M., Sten, A., and Monteiro, 
H.P. (2002). Effects of lipopolysaccharide on low- and high-density cultured rabbit 
vascular smooth muscle cells: differential modulation of nitric oxide release ERK1/ERK2 
MAP kinase activity, protein tyrosine phosphatase activity, and DNA synthesis. Brazilian 
J: Med. Biol. Res. 35, 181-190. 
Barchowsky, A., Dudek, E.J., Treadwell, M.D., and Wetterhahn, K.E. (1996). Arsenic 
induces oxidant stress and NF-kB activation in cultured aortic endothelial cells. Free 
Radic. Biol. Med. 21, 783-790. 
Barchowsky, A., Roussel, R.R., Klei, L.R., James, P.E., Ganju, N., Smith, K.R., and 
Dudek, E.J. (1999). Low levels of arsenic trioxide stimulate proliferative signals in 
primary vascular cells without activating stress effector pathways. Toxicol. Applied 
Pharmacol. 159, 65-75. 
Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A., and Freeman, B.A. (1990). 
Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury 
from nitric oxide and superoxide. Proc. Natl. Aca. Sci. U.S.A, 87, 1620-1624. 
Brooks, P C., Montgomery, A.M.P., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., and 
Cheresh, D.A. (1994). Integrin avP3 antagonists promote tumor regression by inducing 
apoptosis of angiogenic blood vessels. Cell 79, 1157-1164-
48 
Bunderson, M., Coffin, J.D., and Beall, H.D. (2002). Arsenic induces peroxynitrite 
generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible 
role in atherosclerosis. Toxicol. Applied Pharmacol. 184, 11-18. 
Charnock-Jones, D.S., Kaufmann, P., and Mayhew, T.M. (2004). Aspect of human 
fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 25, 103-
113. 
Chen, A., Cao, E-H., Zhang, T-C, and Qin, J-F (2002). Arsenite-induced reactive oxygen 
species and the repression of a-tocopherol in the MGC-803 cells. Eur. J of Pharmacol. 
448, 11-18. 
Concha, G., Vogler, G., Lezcano, D., Nermell, B., and Vahter, M. (1998). Exposure to 
inorganic arsenic metabolites during early human development. Toxicol. Sci. 44, 185-
190. 
Coffin, J.D., and Poole, T.J. (1988). Embryonic vascular development: 
immunohistochemical identification of the origin and subsequent morphogenesis of the 
major vessel primordia in quail embryos. Development. 102, 735-48. 
Dencker, L., Danielsson, B., Khayat, A., and Lindgren, A. (1983). Disposition of metals 
in the embryo and fetus. In: Clarkson, TW, Nordberg GF, Sager PR, eds. Reproductive 
and developmental toxicity of metals. New York: plenum; 607-31. 
Deneke, S., M., Induction of cysteine transport in bovine pulmonary artery endothelial 
cells by sodium arsenite. (1992). Biochim. Biophys. Acta. 1109, 127-131. 
Desesso, J.M., Facobson, C.F., Scialli, A.R., Farr, C.H., and Holson, J.F. (1998). An 
assessment of the developmental toxicity of inorganic arsenic. Reproductive Toxicol. 12, 
385-433-
Dimmeler, S., and Zeiher, A.M. (2000). Endothelial cell apoptosis in angiogenesis and 
vessel regression. Circ. Res. 87, 434-39 
Donnay I, Bernard S, Feugang JM, Kaidi S, and Moens A. (2000). Effect of cyanide 
(KCN) on bovine embryo development and apoptosis. Theriogenology (abstract) 53: 350. 
Eastman, N.J. (1931). The arsenic content of the human placenta following arsphenamine 
therapy. Am. J. Obstet. Gynecol. 21, 60-4. 
Folkman, J., and Shing, Y. (1992). Angiogenesis. J. Biol. Chem. 267, 10931-4 
Gordon, J.D., Shifren, J.L., Foulk, R.A., Taylor, R.N., and Jaffe, R.B. (1995). 
Angiogenesis in the human female reproductive tract. Obstet. Gynecol. Surv 50, 688-97. 
49 
Gow, A. J., Duran, D., Malcolm, S., and Ischiropoulos, H. (1996). Effects of 
peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. 
FEBS Lett. 385, 63-66. 
Gurr, J.R., Yih, L.H., Samikkannu, T., Bau, D.T., Lin, S.Y., and Jan, K.Y. (2003). Nitric 
oxide production by arsenite. Mutat. Res. 533, 173-182. 
Harrison, W.P., and Hodd, R.D. (1981). Prenatal effects following exposure of hamsters 
to sodium arsenite by oral or intraperitoneal routes. Teratology 23, 40A. 
He, H., Venema, V. J., Gu, X., Venema, R. C., Marrero, M. B., and Caldwell, R. B 
(1999). Vascular endothelial growth factor signals endothelial cell production of nitric 
oxide and prostacyclin through flk-l/KDR activation of c-Src. J. Biol. Chem. 274, 25130-
25135. 
Holson, J.F., Stump, D.G., Clevidence, K.J., Knapp, J.F., and Farr, C.H. (2000). 
Evaluation of the prenatal developmental toxicity of orally administered arsenic trioxide 
in rats. Food Chem. Toxicol. 38, 459-466. 
Hood, R.D., Thacker, G.R., Patterson, B.L., and Szczech, G.M. (1978). Prenatal effects 
of oral vs. intraperitoneal sodium arsenate in mice. J- Environ. Pathol. Toxicol. 1, 857-64. 
Hood, R.D. (1972). Effects of sodium arsenite on fetal development. Bull. Environ. 
Contam. Toxicol. 7, 216-22. 
Hopenhayn-Rich, C., Browning, S.R., Hertz-Picciotoo, I., Ferreccio, C., Peralta, C., and 
Gibb, H. (2000). Chronic arsenic exposure and risk of infant mortality in tow areas of 
Chile. Environ. Health Perspect. 108, 667-73. 
Hopenhayn, C., Ferreccio, C., Browning, S.R., Huang, B., Peralta, C., Gibb, H., and 
Hertz-Picciotto, I. (2003). Arsenic exposure from drinking water and birth weight. 
Epidemiology. 14, 593-602. 
Jenkins, D.C., Charles, I.G., Thomsen, L.L., Moss, D.W., Holmes, L.S., Baylis, S.A., 
Rhodes, P., Westmore, K., Emson, P.C., and Moncada, S. (1995). Roles of NO in tumor 
growth. Proc. Natl. Acad. Sci. USA 92, 4392-4396. 
Kao, Y-H., Yu, C-L., Chang, L., W., and Yu, H-S. (2003). Low concentration of arsenic 
induced vascular endothelial growth factor and nitric oxide release and stimulate 
angiogenesis in vivo. Chem. Res. Toxicol., 16, 460-468. 
Kochhar, T.S., Howard, W., Hoffman, S., and Brammer-Carleton, L. (1996). Effect of 
trivalent and pentavalent arsenic in causing chromosome alterations in cultured Chinese 
hamster ovary (CHO) cells. Toxicol. Lett. 84, 37-42. 
50 
Krininger, C.E., Stephens, S. H., and Hansen, P. J. (2002). Developmental changes in 
inhibitory effects of arsenic and heat shock on growth of pre-implantation bovine 
embryos. Mol. Reproduction development 63, 335-340. 
Lai, P., K., and Chakraborty, C. (2001). Role of nitric oxide in carcinogenesis and tumor 
progression, Lancet Oncol. 2, 149-156. 
Lee, MY, Bae, ON, Chung, SM, Kang, KT, Lee, JY, and Chung, JH. (2002). 
Enhancement of platelet aggregation and thrombus formation by arsenic in drinking 
water: a contributing factor to cardiovascular disease. Toxicol. Pharmacol. 179, 83-88. 
Lee, T C., Huang, R.Y., and Jan, K.Y. (1985). Sodium arsenite enhances the cytotoxicity, 
clastogenicity and 6-thioguanine-resistant mutagenicity of ultraviolet light in Chinese 
hamster ovary cells. Mutat. Res. 148, 83-89. 
Li, Y., and Zhu, H. (1997). A study on the relation between nitric oxide and abnormal 
development of embryos. Wei Sheng Yan Jiu. 26, 162-6. 
Lindgren, A., Danielsson, B.R.G., Denckler, L., and Vahter, M. (1984). Embryo-toxicity 
of arsenite and arsenate: distribution in pregnant mice and monkeys and effects on 
embryonic cells in vitro. Acta. Pharmacol. Toxicol. 54, 311-20. 
Liu, F., and Jan, K.Y. (2000). DNA damage in arsenite- and cadmium-treated bovine 
aortic endothelial cells, Free Radic. Biol. Med. 28, 55-63. 
Lynn, S., Gurr, J. R., Lai, H. T., and Jan, K. Y. (2000). NADH oxidase activation is 
involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle 
cells. Circ. Res. 86, 514-519-
Morrissey, R.E., and Mottet, N.K. (1983). Arsenic-induced exencephaly in the mouse and 
associated lesions occurring during neurulation. Teratology 28, 399-411. 
Orzsonyi, M. B., Bereczky, A., Rudnai, P., Csanady, M., and Horvath, A. (1992). 
Epidemiologic studies on human subjects exposed to arsenic in drinking water in 
southern Hungary. Arch. Toxicol. 66, 77-78. 
Poole, T.J., and Coffin, J.D. (1989). Vasculogenesis and angiogenesis: two distinct 
morphogenetic mechanisms establish embryonic vascular pattern. J Exp. Zool. 251, 224-
31. 
Ranta, V., Mikkola, T., Ylikorkala, O., Viinikka, L., and Orpana, A. (1998). Reduced 
viability of human vascular endothelial cells cultured on Matrigel™. J Cellular Physiol. 
176, 92-98. 
51 
Roboz, G., Dias, S., Lam, G., Lane, W.J., Soignet, S.L., Warrell, R.P., and Rafii, S. 
(2000). Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and 
may exert an antileukemic effect via inhibition of angiogenesis. Blood 96, 1525-30. 
Rossman, T G., Stone, D., Molina, M., and Troll, W. (1980). Absence of arsenite 
mutagenicity in E. coli and Chinese hamster cells. Environ. Mutagen. 2, 307-314 
Scott, N., Hatlelid, K.M., Mackenzie, N.E., and Carter, D.E. (1993). Reaction of arsenic 
(III) and arsenic (V) species with glutathione. Chem. Res. Toxicol. 6, 102-106. 
Soucy, N.V., Ihnat, M.A., Kamat, C.D., Hess, L., Post, M.J., Klei, L.R., Clark, C., and 
Barchowsky, A. (2003). Arsenic stimulates angiogenesis and tumorigenesis in vivo. 
Toxicol. Sci. 76, 271-9. 
Stump, D.G., Holson, J.F., Fleeman, T.L., Nemec, M.D., and Farr, C.H. (1999). 
Comparative effects of single intraperitoneal or oral doses of sodium arsenate 
or arsenic trioxide during in utero development. Teratology. 60,283-91. 
Tabacova, S., Hunter, E.S., and Gladen, B.C. (1996). Developmental toxicity of inorganic 
arsenic in whole embryo culture: oxidation state, dose, time, and gestational age 
dependence. Toxicol. Applied pharmacol. 138, 298-307. 
Tchounwou, P.B., Wilson, B., and Ishaque, A. (1999). Important consideration in the 
development of public health advisories for arsenic and arsenic-containing compounds in 
drinking water. Rev. Environ. Health. 14, 211-29 
Tonner-Navarro, L.E., Halmes, N.C., and Roberts, S.M. (1998). Technical report: risk 
assessment of organic versus inorganic arsenic. Prepared for the division of waste 
management, Florida department of environmental protection. 
Tsai, S.H., Hsieh, M.S., Chen, L., Liang, Y.C., Lin, J.K/, and Lin, S.Y. (2001). 
Suppression of Fas ligand expression on endothelial cells by arsenite through reactive 
oxygen species. Toxicol. Lett. 123, 11-19. 
Vahter, M., and Concha, G. (2001). Role of metabolism in arsenic toxicity. Pharmacol. 
Toxicol. 89, 1-5. 
Van Der Zee, R., Murohara, T., Luo, Z., Zollmann, F., Passeri, J., Lekutat, C., and Isner, 
J. M. (1997). Vascular endothelial growth factor/vascular permeability factor augments 
nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 
95, 1030-1037. 
Waugh, J.L.T. Arsenic. In: Parker SP, Weil J, Richman B, eds. McGraw-Hill 
Encyclopedia of Science and Technology, 5th ed, vol. 1. New York: McGraw-Hill; 1982: 
715-18. 
52 
Yang, C.Y., Chang, C.C., Tsai, S.S., Chuang, H.Y., Ho, C.K., and Tu, T.N. (2003). 
Arsenic in drinking water and adverse pregnancy outcome in an arseniasis-endemic area 
in northeastern Taiwan. Environ Res. 91, 29-34. 
Yager, J W., and Wiencke, J.K. (1997). Inhibition of poly (ADP-ribose) polymerase by 
arsenite. Mutat. Res. 386, 345-351. 
Zygmunt, M., Herr, F., Munstedt, K., Lang, U., and Liang, O.D. (2003). Angiogenesis 
and vasculogenesis in pregnancy. Eur. J. of Obstet. Gynecol. Reproductive Biol. 110, 
S10-18. 
53 
